Magnesium Sulfate for Bronchiolitis, Viral

Phase-Based Progress Estimates
Bronchiolitis, Viral+1 More
Magnesium Sulfate - Drug
< 18
All Sexes
What conditions do you have?

Study Summary

This trial will evaluate the effect of magnesium sulfate on bronchiolitis, a common respiratory illness in infants.

Eligible Conditions
  • Bronchiolitis, Viral

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 hours post bolus of medication versus placebo

Hour 6
Identify the incidence of adverse effects and safety profile of magnesium sulfate
To evaluate the effect of this therapy on clinical respiratory status

Trial Safety

Safety Progress

1 of 3

Side Effects for

36%Pain with injection of propofol
This histogram enumerates side effects from a completed 2012 Phase 4 trial (NCT01342510) in the Control ARM group. Side effects include: Pain with injection of propofol with 36%.

Trial Design

2 Treatment Groups

Magnesium Sulfate
1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Magnesium Sulfate · Has Placebo Group · N/A

Magnesium Sulfate
Experimental Group · 1 Intervention: Magnesium Sulfate · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Magnesium Sulfate · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnesium sulfate
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 hours post bolus of medication versus placebo

Who is running the clinical trial?

University of LouisvilleLead Sponsor
313 Previous Clinical Trials
72,870 Total Patients Enrolled
John W Berkenbosch, MDPrincipal InvestigatorUniversity of Louisville

Eligibility Criteria

Age < 18 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.